Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women

Biomedicine and Pharmacotherapy

Volumn 57, Issue 10, 2003, Pages 471-481

  Miyoshi, Yasuo ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Estrogen; Polymorphism

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ALLELE; BIOSYNTHESIS; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; DNA POLYMORPHISM; ENZYME METABOLISM; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; ETHNIC DIFFERENCE; GENE FUNCTION; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK FACTOR;

EID: 0344012108     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.09.008     Document Type: Article

References (79)

1. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388.
2. Gail M.H., Costantino J.P., Bryant J., Croyle R., Freedman L., Helzlsouer K., et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 91:1999;1829-1846.
3. Weber B.L., Nathanson K.L. Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer. 36:2000;1193-1199.
4. Dunning A.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 8:1999;843-854.
5. Kristensen V.N., Borresen-Dale A.L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res. 462:2000;323-333.
6. Stemmermann G.N. The pathology of breast cancer in Japanese women compared to other ethnic groups: a review. Breast Cancer Res Treat. 18:(Suppl 1):1991;S67-S72.
7. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer. 89:2000;325-328.
8. Miyoshi Y., Takahashi Y., Egawa C., Noguchi S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J. 8:2002;209-215.
9. Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 87:1995;190-197.
10. Thomas H.V., Key T.J., Allen D.S., Moore J.W., Dowsett M., Fentiman I.S., et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer. 76:1997;401-405.
11. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 90:1998;1292-1299.
12. Miyoshi Y., Tanji Y., Taguchi T., Tamaki Y., Noguchi S. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 9:2003;2229-2233.
13. Zuber M.X., Simpson E.R., Waterman M.R. Expression of bovine 17 alpha-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science. 234:1986;1258-1261.
14. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 3:1994;1873-1876.
15. Feigelson H.S., Coetzee G.A., Kolonel L.N., Ross R.K., Henderson B.E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57:1997;1063-1065.
16. Dunning A.M., Healey C.S., Pharoah P.D., Foster N.A., Lipscombe J.M., Redman K.L., et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer. 77:1998;2045-2047.
17. Weston A., Pan C.F., Bleiweiss I.J., Ksieski H.B., Roy N., Maloney N., et al. CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 7:1998;941-944.
18. Helzlsouer K.J., Huang H.Y., Strickland P.T., Hoffman S., Alberg A.J., Comstock G.W., et al. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 7:1998;945-949.
19. Haiman C.A., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Speizer F.E., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 59:1999;1015-1020.
20. Bergman-Jungestrom M., Gentile M., Lundin A.C., Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer. 84:1999;350-353.
21. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59:1999;4870-4875.
22. Hamajima N., Iwata H., Obata Y., Matsuo K., Mizutani M., Iwase T., et al. No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res. 91:2000;880-885.
23. Spurdle A.B., Hopper J.L., Dite G.S., Chen X., Cui J., McCredie M.R., et al. CYP17 promoter polymorphism and breast cancer in Australian women under age 40 years. J Natl Cancer Inst. 92:2000;1674-1681.
24. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer. 36:2000;2375-2379.
25. Mitrunen K., Jourenkova N., Kataja V., Eskelinen M., Kosma V.M., Benhamou S., et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 9:2000;1343-1348.
26. Feigelson H.S., McKean-Cowdin R., Coetzee G.A., Stram D.O., Kolonel L.N., Henderson B.E. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 61:2001;785-789.
27. Wu A.H., Seow A., Arakawa K., Van Den Berg D., Lee H.P., Yu M. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer. 104:2003;450-457.
28. Feigelson H.S., Shames L.S., Pike M.C., Coetzee G.A., Stanczyk F.Z., Henderson B.E. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58:1998;585-587.
29. Miyoshi Y., Ando A., Ooka M., Shiba E., Taguchi T., Tamaki Y., et al. Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. Cancer Lett. 195:2003;81-86.
30. Kristensen V.N., Haraldsen E.K., Anderson K.B., Lonning P.E., Erikstein B., Karesen R., et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res. 59:1999;2825-2828.
31. Kuligina E.S., Togo A.V., Suspitsin E.N., Grigoriev M.Y., Pozharisskiy K.M., Chagunava O.L., et al. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett. 156:2000;45-50.
32. Mendelson C.R., Means G.D., Mahendroo M.S., Corbin C.J., Steinkampf M.P., Graham-Lorence S., et al. Use of molecular probes to study regulation of aromatase cytochrome P-450. Biol Reprod. 42:1990;1-10.
33. O'Neill J.S., Elton R.A., Miller W.R. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J (Clin Res Ed). 296:1988;741-743.
34. Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P., Borresen-Dale A.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics. 8:1998;43-48.
35. Siegelmann-Danieli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer. 79:1999;456-463.
36. Healey C.S., Dunning A.M., Durocher F., Teare D., Pharoah P.D., Luben R.N., et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis. 21:2000;189-193.
37. Haiman C.A., Hankinson S.E., Spiegelman D., De Vivo I., Colditz G.A., Willett W.C., et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer. 87:2000;204-210.
38. Baxter S.W., Choong D.Y., Eccles D.M., Campbell I.G. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis. 22:2001;347-349.
39. Lee K.M., Abel J., Ko Y., Harth V., Park W.Y., Seo J.S., et al. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br J Cancer. 88:2003;675-678.
40. Kristensen V.N., Harada N., Yoshimura N., Haraldsen E., Lonning P.E., Erikstein B., et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 19:2000;1329-1333.
41. Nativelle-Serpentini C., Lambard S., Seralini G.E., Sourdaine P. Aromatase and breast cancer: W39R, an inactive protein. Eur J Endocrinol. 146:2002;583-589.
42. Probst-Hensch N.M., Ingles S.A., Diep A.T., Haile R.W., Stanczyk F.Z., Kolonel L.N., et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 6:1999;165-173.
43. Suspitsin E.N., Grigoriev M.Y., Togo A.V., Kuligina E.S., Belogubova E.V., Pozharisski K.M., et al. Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur J Cancer. 38:2002;1911-1916.
44. Michnovicz J.J., Rosenberg D.W. Oxidative metabolism of estrogens in rat intestinal mitochondria. Biochem Pharmacol. 43:1992;1847-1852.
45. Taioli E., Trachman J., Chen X., Toniolo P., Garte S.J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res. 55:1995;3757-3758.
46. Bailey L.R., Roodi N., Verrier C.S., Yee C.J., Dupont W.D., Parl F.F. Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African-Americans. Cancer Res. 58:1998;65-70.
47. Ishibe N., Hankinson S.E., Colditz G.A., Spiegelman D., Willett W.C., Speizer F.E., et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 58:1998;667-671.
48. Huang C.S., Shen C.Y., Chang K.J., Hsu S.M., Chern H.D. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer. 80:1999;1838-1843.
49. Krajinovic M., Ghadirian P., Richer C., Sinnett H., Gandini S., Perret C., et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer. 92:2001;220-225.
50. da Fonte de Amorim L., Rossini A., Mendonca G., Lotsch P., de Almeida Simao T., de Moura Gallo C., et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian women. Cancer Lett. 181:2002;179-186.
51. Ambrosone C.B., Freudenheim J.L., Graham S., Marshall J.R., Vena J.E., Brasure J.R., et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 55:1995;3483-3485.
52. Moysich K.B., Shields P.G., Freudenheim J.L., Schisterman E.F., Vena J.E., Kostyniak P., et al. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 8:1999;41-44.
53. Basham V.M., Pharoah P.D., Healey C.S., Luben R.N., Day N.E., Easton D.F., et al. Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk. Carcinogenesis. 22:2001;1797-1800.
54. Laden F., Ishibe N., Hankinson S.E., Wolff M.S., Gertig D.M., Hunter D.J., et al. Polychlorinated biphenyls, cytochrome P450 1A1, and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 11:2002;1560-1565.
55. Law M.R. Genetic predisposition to lung cancer. Br J Cancer. 61:1990;195-206.
56. Sladek N.E. Transient induction of increased aldehyde dehydrogenase 3A1 levels in cultured human breast (adeno)carcinoma cell lines via 5′-upstream xenobiotic, and electrophile, responsive elements is, respectively, estrogen receptor-dependent and -independent. Chem Biol Interact. 143-144:2003;63-74.
57. Brockdorff B.L., Skouv J., Reiter B.E., Lykkesfeldt A.E. Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines. Int J Cancer. 88:2000;902-906.
58. Kharat I., Saatcioglu F. Antiestrogenic effects of 2,3,7,8- tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem. 271:1996;10533-10537.
59. Taioli E., Bradlow H.L., Garbers S.V., Sepkovic D.W., Osborne M.P., Trachman J., et al. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev. 23:1999;232-237.
60. Jefcoate C.R., Liehr J.G., Santen R.J., Sutter T.R., Yager J.D., Yue W., et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr. 27:2000;95-112.
61. Larsen M.C., Angus W.G., Brake P.B., Eltom S.E., Sukow K.A., Jefcoate C.R. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res. 58:1998;2366-2374.
62. Bailey L.R., Roodi N., Dupont W.D., Parl F.F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58:1998;5038-5041.
63. Zheng W., Xie D.W., Jin F., Cheng J.R., Dai Q., Wen W.Q., et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 9:2000;147-150.
64. De Vivo I., Hankinson S.E., Li L., Colditz G.A., Hunter D.J. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 11:2002;489-492.
65. Kocabas N.A., Sardas S., Cholerton S., Daly A.K., Karakaya A.E. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch Toxicol. 76:2002;643-649.
66. Li D.N., Seidel A., Pritchard M.P., Wolf C.R., Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics. 10:2000;343-353.
67. Watanabe J., Shimada T., Gillam E.M., Ikuta T., Suemasu K., Higashi Y., et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics. 10:2000;25-33.
68. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 19:1998;1-27.
69. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 6:1996;243-250.
70. Lavigne J.A., Goodman J.E., Fonong T., Odwin S., He P., Roberts D.W., et al. The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells. Cancer Res. 61:2001;7488-7494.
71. Thompson P.A., Shields P.G., Freudenheim J.L., Stone A., Vena J.E., Marshall J.R., et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 58:1998;2107-2110.
72. Millikan R.C., Pittman G.S., Tse C.K., Duell E., Newman B., Savitz D., et al. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis. 19:1998;1943-1947.
73. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59:1999;4870-4875.
74. Hamajima N., Matsuo K., Tajima K., Mizutani M., Iwata H., Iwase T., et al. Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. Int J Clin Oncol. 6:2001;13-18.
75. Mitrunen K., Jourenkova N., Kataja V., Eskelinen M., Kosma V.M., Benhamou S., et al. Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 10:2001;635-640.
76. Bergman-Jungestrom M., Wingren S. Catechol-O-methyltransferase (COMT) gene polymorphism and breast cancer risk in young women. Br J Cancer. 85:2001;859-862.
77. Yim D.S., Parkb S.K., Yoo K.Y., Yoon K.S., Chung H.H., Kang H.L., et al. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics. 11:2001;279-286.
78. Feigelson H.S., McKean-Cowdin R., Coetzee G.A., Stram D.O., Kolonel L.N., Henderson B.E. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 61:2001;785-789.
79. Miyoshi Y., Tanji Y., Taguchi T., Tamaki Y., Noguchi S. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 9:2003;2229-2233.